Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Core Viewpoint - Cabaletta Bio, Inc. is participating in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its focus on developing curative targeted cell therapies for autoimmune diseases [1]. Company Overview - Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company dedicated to creating the first curative targeted cell therapies specifically for patients with autoimmune diseases [3]. - The company utilizes the CABA™ platform, which includes two complementary strategies aimed at advancing engineered T cell therapies that could provide deep, durable, and potentially curative treatments for a wide range of autoimmune diseases [3]. - The lead strategy, CARTA (Chimeric Antigen Receptor T cells for Autoimmunity), focuses on the development of rese-cel, a fully human CD19-CAR T cell investigational therapy containing 4-1BB [3]. - Rese-cel is currently under evaluation in the RESET™ (REstoring SElf-Tolerance) clinical development program, which spans multiple therapeutic areas including rheumatology, neurology, and dermatology [3]. - Cabaletta Bio is headquartered in Philadelphia, PA [3].